Form 4: Baker Bros. Exits IGM Biosciences Post-Merger
Statement of Changes in Beneficial Ownership (Form 4)
Baker Bros. Advisors LP and related entities report the disposition of all their shares in IGM Biosciences, Inc. following its acquisition by Concentra Biosciences, LLC.
Summary
- Baker Bros. Advisors LP, along with Baker Brothers Life Sciences LP, 667, L.P., Felix Baker, and Julian Baker, reported the disposition of all their beneficial ownership in IGM Biosciences, Inc. (IGMS).
- The disposition occurred on August 14, 2025, coinciding with the completion of a tender offer by Concentra Biosciences, LLC to acquire all outstanding shares of IGM Biosciences.
- Shareholders received $1.247 per share in cash plus one non-transferable contractual contingent value right (CVR) for each share.
- The transaction was pursuant to an Agreement and Plan of Merger dated July 1, 2025, where Concentra Merger Sub V, Inc. merged into IGM Biosciences, with IGM Biosciences surviving as a subsidiary of Concentra Biosciences.
- Felix J. Baker resigned as a director of IGM Biosciences immediately prior to the merger's closing.
- The reporting persons, other than Felix J. Baker, are no longer deemed directors by deputization for Section 16 purposes.
Sentiment
Score: 5
Explanation: The filing is a factual report of a completed corporate transaction (merger and tender offer), which was previously announced. It does not contain new positive or negative operational news, but rather confirms the finalization of an expected event.
Positives
- The successful completion of the tender offer and merger provides liquidity to former IGM Biosciences shareholders, including the reporting persons.
- The transaction includes a contingent value right, offering potential future value based on specific milestones.
Negatives
- The reporting persons, including Baker Bros. Advisors LP and its affiliates, no longer hold any beneficial ownership in IGM Biosciences.
- Felix J. Baker has resigned from the board of directors, ending direct representation for Baker Bros. on the IGM Biosciences board.
Risks
- The value of the contingent value right (CVR) is subject to future events and may not materialize, representing a potential risk to the full consideration received by former shareholders.
Future Outlook
IGM Biosciences, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC, and will no longer operate as an independent publicly traded entity. Its future operations and strategic direction will be determined by Concentra Biosciences.
Management Comments
- Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, resigned as a director of IGM Biosciences, Inc. immediately prior to the closing of the merger with Concentra Biosciences, LLC.
Industry Context
This filing reflects a completed acquisition within the biotechnology sector, a common occurrence as larger pharmaceutical or biotech companies seek to expand their pipelines or acquire promising technologies through strategic mergers and acquisitions.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Felix J. Baker | NA | 08/14/2025 | Resignation immediately prior to the closing of the merger with Concentra Biosciences, LLC. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Resignation | Felix J. Baker resigned as a director of IGM Biosciences, Inc. immediately prior to the merger closing. | 08/14/2025 | Removes direct representation of Baker Bros. on the IGM Biosciences board, consistent with the company becoming a subsidiary. |
| Beneficial Ownership Status | Reporting persons (other than Felix J. Baker) are no longer deemed directors by deputization for Section 16 purposes. | 08/14/2025 | Reflects the cessation of significant influence or control by Baker Bros. entities over IGM Biosciences post-acquisition. |
Related Party Transactions
- The filing details the complex indirect pecuniary interests of Julian C. Baker and Felix J. Baker through various Baker Bros. entities (e.g., Baker Biotech Capital, L.P., 667, L.P., Baker Brothers Life Sciences, L.P.) in the disposed securities. This clarifies their beneficial ownership structure related to the transaction.
Stakeholder Impact
- Shareholders of IGM Biosciences received cash and contingent value rights for their shares, completing the monetization of their investment.
- Employees of IGM Biosciences are now part of Concentra Biosciences, LLC, with their employment terms subject to the new parent company's policies.
Next Steps
- IGM Biosciences will operate as a subsidiary of Concentra Biosciences, LLC.
- The contingent value rights (CVRs) will be subject to their specific terms and conditions, which may include future milestones or events that trigger payments.
Key Dates
| Date | Description |
|---|---|
| 07/01/2025 | Date of Agreement and Plan of Merger between IGM Biosciences, Concentra Biosciences, LLC, and Concentra Merger Sub V, Inc. |
| 08/14/2025 | Effective time of the merger and completion of the tender offer; date of earliest transaction reported. |
| 08/18/2025 | Filing date of the Form 4. |
Keywords
IGM Biosciences, IGMS, Concentra Biosciences, Baker Bros. Advisors, Merger, Acquisition, Tender Offer, Beneficial Ownership, Form 4, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.